FDA Accepts Sanofi’s New Drug Application for Basal Insulin Toujeo®

The U.S. Food and Drug Administration (FDA) has accepted for review the company’s New Drug Application (NDA) for Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL),an investigational basal insulin (Sanofi)